Products
By Team
Sales
Multithread effectively and personalize outreach to convert deals faster
Social Media Marketing
Elevate social presence and drive business growth from social media
RevOps
Identify and prioritize high-intent leads, and improve sales effectiveness
Events & Field Marketing
Find and connect with ICP attendees, and improve event outcomes
Resources
.png)
.png)
freenome
Overview
Freenome is a leading biotechnology company at the forefront of early cancer detection, developing a novel multiomics platform to analyze circulating biomarkers in blood samples. By integrating machine learning with advanced molecular biology, Freenome aims to identify cancer signals at their earliest stages, offering a non-invasive alternative to traditional screening methods. Focused on revolutionizing cancer diagnostics, Freenome operates within the competitive liquid biopsy market, positioning itself as a frontrunner in the development and commercialization of accurate and accessible early cancer detection solutions.
freenome's headcount breakdown by department
| Department | HeadCount |
|---|---|
Administrative | 2 |
Consulting | 0 |
Service | 2 |
Design | 0 |
Education | 0 |
Freenome's organizational structure is heavily weighted towards research and development, reflecting the company's deep focus on scientific innovation in cancer detection. The large 'Research' department (86 employees) and 'Technical' department (63 employees), complemented by a sizable 'Medical' team (33 employees), underscore Freenome's commitment to cutting-edge research, technological advancement, and clinical validation of its platform. The 'Operations' department (23 employees) indicates a significant investment in scaling up sample processing and analysis capabilities. The existence of an 'Other Department' consisting of a significant 64 employees may house functions like engineering or data science. The relatively small sizes of the 'Finance' (10), 'HR' (7), 'Legal' (5), and 'Marketing' (5) departments suggest that the company is in a phase of scaling operations, moving beyond pure R&D and preparing for potential commercialization. The lean 'Sales' headcount (1) likely indicates a business model reliant on partnerships with pharmaceutical companies, collaborations with academic medical centers and research institutions, and potential future licensing agreements, rather than a direct-to-consumer sales approach. The workforce allocation indicates a focus on demonstrating clinical efficacy and navigating the regulatory approval process, positioning Freenome as a biotechnology company poised for growth in the precision oncology space.
freenome's employees by locations
Employee Count by Country
Total: 331 employees
Freenome's global workforce distribution demonstrates a strong concentration in the United States (319 employees), highlighting the company's origins and primary operational base. While the organization maintains a presence in several other countries, including Canada, Switzerland, Turkey, Philippines, Austria, Netherlands, and the United Kingdom, the relatively small employee counts (single digits) suggest a largely domestic focus. This geographic strategy likely reflects the company's initial emphasis on U.S.-based clinical trials, engagement with the U.S. Food and Drug Administration (FDA) regulatory framework, and targeting of the U.S. healthcare market. The limited presence in European countries suggests potential exploration of European markets or collaborations with European research organizations. The employees in Turkey and Philippines likely represent remote staff supporting specific technical or operational needs. Overall, Freenome's geographic strategy appears aligned with a business model prioritizing the U.S. market while laying the groundwork for future international expansion and strategic alliances. The data indicates a U.S.-centric organization in the early stages of evaluating its global market opportunities.
Want to stay ahead of freenome's org changes?
Get alerts when hiring spikes or teams shift focus
Track changes vs. competitors
Spot warm GTM signals early